ADC Therapeutics SA Market Cap 2019-2022 | ADCT
ADC Therapeutics SA market cap history and chart from 2019 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. ADC Therapeutics SA market cap as of September 23, 2022 is $0.38B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.376B | $0.034B |
| ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $150.984B | 9.16 |
| GSK (GSK) | United Kingdom | $59.709B | 7.17 |
| Bio-Rad Laboratories (BIO.B) | United States | $12.433B | 27.47 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.873B | 0.00 |
| QIAGEN (QGEN) | Netherlands | $9.383B | 15.71 |
| Ginkgo Bioworks Holdings (DNA) | United States | $4.998B | 0.00 |
| Arcus Biosciences (RCUS) | United States | $1.819B | 35.51 |
| Myovant Sciences (MYOV) | United Kingdom | $1.614B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.040B | 6.03 |
| Zymeworks (ZYME) | Canada | $0.305B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.105B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.081B | 0.00 |
| SQZ Biotechnologies (SQZ) | United States | $0.068B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.041B | 0.00 |
